Cargando…
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin
Targeted radioiodine therapy for thyroid cancer is based on selective stimulation of Na(+)/I(−) Symporter (NIS)-mediated radioactive iodide uptake (RAIU) in thyroid cells by thyrotropin. Patients with advanced thyroid cancer do not benefit from radioiodine therapy due to reduced or absent NIS expres...
Autores principales: | Lakshmanan, Aparna, Scarberry, Daniel, Green, Jill A., Zhang, Xiaoli, Selmi-Ruby, Samia, Jhiang, Sissy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741640/ https://www.ncbi.nlm.nih.gov/pubmed/26397139 |
Ejemplares similares
-
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy
por: Ke, Chien-Chih, et al.
Publicado: (2012) -
Implications of Na(+)/I(-) Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy
por: Martín, Mariano, et al.
Publicado: (2018) -
Nevirapine Increases Sodium/Iodide Symporter-Mediated Radioiodide Uptake by Activation of TSHR/cAMP/CREB/PAX8 Signaling Pathway in Dedifferentiated Thyroid Cancer
por: Shang, Hongxia, et al.
Publicado: (2020) -
Personalized radioiodine therapy for thyroid cancer patients with known disease
por: Jhiang, Sissy M, et al.
Publicado: (2021) -
Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy
por: Renier, Corinne, et al.
Publicado: (2016)